COMP <GO>
NOV vs PG // ENTERPRISE SCALE & MARKET CAP
NOV Inc. (NYSE) VS. Procter & Gamble Company (The) (NYSE) • 15-METRIC TALLY: NOV 4
— PG 11
▲ ENTERPRISE SCALE & MARKET CAP LEADER: PG
LAST: $19.29 (-0.36%) • MKT CAP: $6.90B
market-cap
$6.90B
LAST: $161.57 (+0.61%) • MKT CAP: $372.21B
market-cap
$372.21B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NOV VS. PG)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NOV | PG | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 20.20% | 51.20% | -31.00 | PG | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 6.10% | 25.40% | -19.30 | PG | /roic <GO> |
| EV/EBITDA & P/E Valuation | 8.7x | 16.2x | -7.50 | NOV | /valuation <GO> |
| Free Cash Flow Yield | 12.69% | 3.77% | +8.92 | NOV | /fcf-yield <GO> |
| Operating Margin | 5.60% | 24.30% | -18.70 | PG | /operating-margins <GO> |
| Net Profit Margin | 1.70% | 19.00% | -17.30 | PG | /net-margins <GO> |
| Revenue Growth (YoY) | -1.40% | 0.30% | -1.70 | PG | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.75% | 2.65% | +0.10 | NOV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.03 | 5.59 | -3.56 | PG | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | PG | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.30% | 6.50% | +0.80 | PG | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.3 | 62.7 | -14.43 | PG | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.11 | 0.87 | +0.24 | NOV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 44.3x | 21.7x | +22.60 | PG | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $6.90B | $372.21B | -$365.31B | PG | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NOV REV | PG REV | NOV GROSS % | PG GROSS % | NOV FCF | PG FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $8.74B | $84.28B | 20.2% | 51.2% | $876.0M | $14.04B |
| FY 2024 | $8.87B | $84.04B | 22.7% | 51.4% | $953.0M | $16.52B |
| FY 2023 | $8.58B | $82.01B | 44.0% | 44.0% | -$243.2M | $13.16B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NOV // BETA 1.11
PG // BETA 0.87